What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oasmia Pharmaceutical AB (publ) investors own include G1 Therapeutics (GTHX) , Amarin (AMRN) , CRISPR Therapeutics (CRSP) , Supernus Pharmaceuticals (SUPN) , Verastem (VSTM) , Akari Therapeutics (AKTX) , Nightstar Therapeutics (NITE) , Novavax (NVAX) and OpGen (OPGN) .

NASDAQ:OASM

Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free OASM Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.02
▼
$0.02
50-Day Range: $1.30
▼
$1.62
52-Week Range: $0.94
▼
$5.70

Volume: N/A
Average Volume: 98,414 shs
Market Capitalization: $1.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Oasmia Pharmaceutical AB (publ) alerts:

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

OASM Stock News Headlines

March 23, 2024 | morningstar.com

Lipigon Pharmaceuticals AB LPGO

March 6, 2024 | gurufocus.com

LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcript

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 6, 2024 | gurufocus.com

Oasmia Pharmaceutical AB (publ) - Special Call Transcript

February 8, 2024 | finance.yahoo.com

Resurs Holding AB (publ) (RESURS.ST)

January 6, 2024 | morningstar.com

QuiaPEG Pharmaceuticals Holding AB QUIA

November 29, 2023 | investing.com

Newbury Pharmaceuticals AB (NEWBRY)

September 14, 2023 | investing.com

Lipigon Pharmaceuticals AB (LPGO)

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

August 25, 2023 | investing.com

Speqta publ AB (SPEQT)

August 25, 2023 | seekingalpha.com

PRXXF Paradox Interactive AB (publ)

February 26, 2023 | seekingalpha.com

OXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2M

March 11, 2022 | stockhouse.com

Orexo appoints Fredrik Järrsten as new CFO

November 29, 2021 | finanznachrichten.de

Notice of extra general meeting in Terranet AB

July 22, 2021 | investing.com

Fancy Wood Industries PCL (FANCY)

See More Headlines

Receive OASM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oasmia Pharmaceutical AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OASM
CUSIP: N/A
CIK: 1607245
Web: www.oasmia.com
Phone: (461) 850-5440
Fax: N/A
Employees: 57
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,950,000.00
Net Margins: -8,633.64%
Pretax Margin: N/A
Return on Equity: -43.94%
Return on Assets: -28.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.80
Quick Ratio: 0.73

Sales & Book Value

Annual Sales: $220,000.00
Price / Sales: 6.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.63 per share
Price / Book: 0.03

Miscellaneous

Outstanding Shares: 74,967,000
Free Float: N/A
Market Cap: $1.50 million
Optionable: Not Optionable
Beta: 0.96

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

François R. Martelet
Chief Executive Officer
Fredrik Järrsten
Chief Financial Officer
Mikael Asp
Chief Technology Officer
Nigel Goodman
Director-Clinical Operations
Carina Eklöw
Director-Global Medical Affairs

Key Competitors

View All Competitors

OASM Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oasmia Pharmaceutical AB (publ) investors own include G1 Therapeutics (GTHX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Supernus Pharmaceuticals (SUPN), Verastem (VSTM), Akari Therapeutics (AKTX), Nightstar Therapeutics (NITE), Novavax (NVAX) and OpGen (OPGN).

This page (NASDAQ:OASM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis

About Oasmia Pharmaceutical AB (publ)

OASM Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

OASM Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info